IHCAMS
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS), founded in 1957, is China's largest national research hospital in hematology. It integrates patient care, fundamental research, education and translation.
With 1,500 beds and 14 clinical centers, the annual number of patients diagnosed and treated at IHCAMS exceeded 300,000 in 2023. The mission of IHCAMS is to set the standard for excellence in medical and patient-centered clinical care and to make major contributions to scientific research that enhances human health in hematology and beyond. As the base for the National Clinical Research Center for Blood Diseases and the National Laboratory of Blood Science, IHCAMS is continually exploring innovative developments in the field of hematology. IHCAMS has been the top-ranked specialty hospital for both clinical care and scientific impact in hematology in China for consecutively 14 years and 11 years respectively.
HISTORY AND ACHIEVEMENTS
IHCAMS has achieved significant milestones in the treatment of adult acute myeloid leukemia (AML), childhood acute lymphoblastic leukemia (ALL), lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), severe aplastic anemia (SAA), and idiopathic thrombocytopenic purpura (ITP).
Below are highlights of its clinical achievements:
Adult AML—nearly 80% of cases achieved complete remission, with a 3-year overall survival rate of over 60%.
Childhood ALL—standardization of diagnosis and treatment of childhood ALL in China, with 98% of patients in complete remission and 5-year event-free survival rate of 85%.
MM—outlined practical guidelines for diagnosis and treatment of the disease in China and conducted systematic cytogenetic research.
MDS—developed a new strategy for diagnosis, classification, prognosis, and treatment of MDS based on Chinese patient data.
Hematopoietic stem cell transplantation (HSCT)—carried out the first autologous HSCT in China in 1986, achieving a long-term survival rate of 70% in patients with acute leukemia; for allogeneic HSCT, a disease-free survival rate of more than 90% for AA patients was achieved.
ITP—set up the first bleeding score for ITP patients in China and analyzed patient quality of life using the SF-36 health status questionnaire.
Hematopathology—established a national reference laboratory operating within the Department of Pathology and Laboratory Medicine that collects more than 20,000 bone marrow biopsies annually, collaborates with more than 100 tertiary hospitals nationally for sample collection, and provides clinical laboratory testing all over China.
As a comprehensive center for hematology, IHCAMS is dedicated to standardizing protocols for diagnosis and treatment, developing innovative technologies and methods for translational medicine in hematological malignancies, and advancing the field of hematology in China.
National K...
IHCAMS launched the National Key Laboratory of Blood Science (NKLBS) in 2023. NKLBS has broad research strengths, with a particular emphasis on regulation and regeneration of hematopoietic stem cells and pathological blood cells, the molecular basis of hematopoietic cell ecosystem, and prediction and precise medicine for blood- related diseases. The relationship among the three hospitals and institutes supports a longstanding focus on bench-to-bedside research, through which discoveries in NKLBS lead to therapies and treatments for patients on an accelerated timetable.
National Clinical
Research Center for Blood Diseases
Research Center for Blood Diseases
The National Clinical Research Center for Blood Diseases (hereinafter referred to as "the Center" ) is the national clinical medical research center that was jointly issued by the Ministry of Science and Technology, the National Health Commission, the Logistics Support Department of the Central Military Commission and the National Medical Products Administration in May, 2019.
National Clinical Research Center for Blood Diseases
The National Clinical Research Center for Blood Diseases (hereinafter referred to as "the Center" ) is the national clinical medical research center that was jointly issued by the Ministry of Science and Technology, the National Health Commission, the Logistics Support Department of the Central Military Commission and the National Medical Products Administration in May, 2019.